Abstract：【Objective】To explore the effect of irbesartan combined with dapagliflozin on vascular elasticity in elderly patients with isolated systolic hypertension (ISH).【Methods】A total of 158 elderly ISH patients admitted to our hospital from May 2022 to June 2024 were selected and divided into the observation group and the control group by the random number table method, with 79 patients in each group. The control group was treated with irbesartan, and the observation group was treated with irbesartan combined with dapagliflozin. Both groups were treated for 24 weeks. Blood pressure levels (24-hour average diastolic blood pressure, 24-hour average systolic blood pressure), vascular elasticity [carotid-femoral pulse wave velocity (cfPWV), ankle-brachial index (ABI), pressure-strain elastic modulus (Ep)], serum inflammatory factors [high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α)] and the incidence of adverse reactions were compared between the two groups before and after treatment.【Results】After treatment, the 24-hour average systolic blood pressure of both groups was lower than that before treatment, and that of the observation group was lower than that of the control group, with a statistically significant difference (P<0.05). There was no statistically significant difference in the 24-hour average diastolic blood pressure between the two groups (P>0.05). After treatment, cfPWV and Ep in the observation group were lower than those in the control group, and ABI was higher than that in the control group, with statistically significant differences (P<0.05). After treatment, the levels of serum hs-CRP and TNF-α in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Irbesartan combined with dapagliflozin can effectively improve the vascular elasticity of elderly ISH patients, significantly reduce systolic blood pressure, inhibit the inflammatory response, and has good safety, which has clinical promotion value.
2025, Vol. 42 
